Jenna L. E. Blum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jenna L. E. Blum has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Shawn M. Davidson
Division of Pulmonary and Critical Care Medicine, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
2 shared publications - Alec R. Koss
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
1 shared publication - Ami Siddharth Bhatt
Stanford University
1 shared publication - Anne Brunet
Department of Genetics, Stanford University, Stanford, CA, USA
1 shared publication - Aravind Natarajan
Department of Genetics, Stanford University, Stanford, CA, USA
1 shared publication Ashley A. Moore
Department of Medicine, Divisions of Hematology and Blood & Marrow Transplantation, Stanford University, Stanford, CA, USA
1 shared publication
Latest Publications
- Open Access
Spatial isotope tracing maps compartmentalized nutrient use across the adult fruit fly
Drosophila melanogaster is a powerful model for studying systemic metabolism. Although metabolism is compartmentalized across tissues, prior work in adult Drosophila has mostly measured it in dissected tissues rather than in situ , limiting the spatial information that can be gained. Here, we combine whole-fly massspectrometry imaging with stable-isotope tracing and flux modeling to quantify metabolic activities across the adult fruit fly in a spatially resolved manner. Across 68 tracer-fed Oregon-R female flies and 187,709 pixels, we map 81 metabolites onto eight annotated regions, including muscle, fat body, gut, and nervous system. Glucose labeling and fitted relative fluxes indicate higher glycolytic and tricarboxylic acid cycle turnover in thoracic muscle than in abdominal fat body; proline labels the nervous system and eye; glutamine the abdominal reproductive system and gut. Alanine carries glucose-derived carbon through the hemolymph and transfers nitrogen into glutamate. In flies bearing yorkie-driven gut tumors, alanine contribution to malate rises in gut and abdomen, and reducing gut alanine uptake lowers tumor burden. Together, this work establishes a framework for quantitative spatial metabolic analysis, showing compartmentalized nutrient use across the adult fruit fly.
Open AccessSpatial isotope tracing maps compartmentalized nutrient use across the adult fruit fly
Drosophila melanogaster is a powerful model for studying systemic metabolism. Although metabolism is compartmentalized across tissues, prior work in adult Drosophila has mostly measured it in dissected tissues rather than in situ , limiting the spatial information that can be gained. Here, we combine whole-fly massspectrometry imaging with stable-isotope tracing and flux modeling to quantify metabolic activities across the adult fruit fly in a spatially resolved manner. Across 68 tracer-fed Oregon-R female flies and 187,709 pixels, we map 81 metabolites onto eight annotated regions, including muscle, fat body, gut, and nervous system. Glucose labeling and fitted relative fluxes indicate higher glycolytic and tricarboxylic acid cycle turnover in thoracic muscle than in abdominal fat body; proline labels the nervous system and eye; glutamine the abdominal reproductive system and gut. Alanine carries glucose-derived carbon through the hemolymph and transfers nitrogen into glutamate. In flies bearing yorkie-driven gut tumors, alanine contribution to malate rises in gut and abdomen, and reducing gut alanine uptake lowers tumor burden. Together, this work establishes a framework for quantitative spatial metabolic analysis, showing compartmentalized nutrient use across the adult fruit fly.
- Open Access
Age-related microbiome metabolites alter RNA splicing and chromatin accessibility in the brain
The gut microbiome generates diverse metabolites that can enter the bloodstream and alter host biology, including brain function. Hundreds of physiologically relevant, gut-brain signaling molecules likely exist; however, there has been no systematic, high-throughput effort to identify and validate them. Here, we integrate computational, in vitro , and in vivo approaches to pinpoint microbiome-derived metabolites whose blood levels change during aging, and that induce corresponding changes in the mouse brain. First, we mine large-scale metabolomics datasets from human cohorts (each n ≥ 1200) to identify 30 microbiome-associated metabolites whose blood levels change with age. We then screen this panel in an in vitro transcriptomic assay to identify metabolites that perturb genes linked to age-related neurodegeneration. We then test four metabolites in an acute-exposure mouse model, and use multi-omic approaches to evaluate their impact on cellular functions in the brain. We confirm the known neurodegeneration-promoting effects of trimethylamine N-oxide (TMAO), including mitochondrial dysfunction, and further discover its disruptive impact on the pathways of glycolysis, GABAergic signaling, and RNA splicing. Additionally, we identify glycodeoxycholic acid (GDCA), a microbiome-derived secondary bile acid, as a potent regulator of chromatin accessibility and suppressor of genes that protect the brain from age-related, neurodegeneration-promoting insults. GDCA also acutely reduces mobility. In summary, we present a scalable framework for linking microbiome metabolites to host pathologies, and apply it to identify microbial metabolites that induce molecular changes related to neurodegeneration.
Open AccessAge-related microbiome metabolites alter RNA splicing and chromatin accessibility in the brain
The gut microbiome generates diverse metabolites that can enter the bloodstream and alter host biology, including brain function. Hundreds of physiologically relevant, gut-brain signaling molecules likely exist; however, there has been no systematic, high-throughput effort to identify and validate them. Here, we integrate computational, in vitro , and in vivo approaches to pinpoint microbiome-derived metabolites whose blood levels change during aging, and that induce corresponding changes in the mouse brain. First, we mine large-scale metabolomics datasets from human cohorts (each n ≥ 1200) to identify 30 microbiome-associated metabolites whose blood levels change with age. We then screen this panel in an in vitro transcriptomic assay to identify metabolites that perturb genes linked to age-related neurodegeneration. We then test four metabolites in an acute-exposure mouse model, and use multi-omic approaches to evaluate their impact on cellular functions in the brain. We confirm the known neurodegeneration-promoting effects of trimethylamine N-oxide (TMAO), including mitochondrial dysfunction, and further discover its disruptive impact on the pathways of glycolysis, GABAergic signaling, and RNA splicing. Additionally, we identify glycodeoxycholic acid (GDCA), a microbiome-derived secondary bile acid, as a potent regulator of chromatin accessibility and suppressor of genes that protect the brain from age-related, neurodegeneration-promoting insults. GDCA also acutely reduces mobility. In summary, we present a scalable framework for linking microbiome metabolites to host pathologies, and apply it to identify microbial metabolites that induce molecular changes related to neurodegeneration.
- Open Access
Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycemic control
Metformin is a therapeutically versatile biguanide drug primarily prescribed for type II diabetes. Despite its extensive use, the mechanisms underlying many of its clinical effects, including attenuated postprandial glucose excursions, elevated intestinal glucose uptake, and increased production of lactate, Lac-Phe and GDF15, remain unclear. Here, we map these and other clinical effects of metformin to intestine-specific mitochondrial complex I inhibition. Using human metabolomic data and an orthogonal genetics approach in male mice, we demonstrate that metformin suppresses citrulline synthesis, a metabolite generated exclusively by small intestine mitochondria, and increases GDF15 by inhibiting the mitochondrial respiratory chain at complex I. This inhibition co-opts the intestines to function as a glucose sink, driving uptake of excess glucose and converting it to lactate and Lac-Phe. Notably, the glucose-lowering effect of another biguanide, phenformin, and berberine, a structurally unrelated nutraceutical, similarly depends on intestine-specific mitochondrial complex I inhibition, underscoring a shared therapeutic mechanism.
Open AccessMetformin inhibits mitochondrial complex I in intestinal epithelium to promote glycemic control
Metformin is a therapeutically versatile biguanide drug primarily prescribed for type II diabetes. Despite its extensive use, the mechanisms underlying many of its clinical effects, including attenuated postprandial glucose excursions, elevated intestinal glucose uptake, and increased production of lactate, Lac-Phe and GDF15, remain unclear. Here, we map these and other clinical effects of metformin to intestine-specific mitochondrial complex I inhibition. Using human metabolomic data and an orthogonal genetics approach in male mice, we demonstrate that metformin suppresses citrulline synthesis, a metabolite generated exclusively by small intestine mitochondria, and increases GDF15 by inhibiting the mitochondrial respiratory chain at complex I. This inhibition co-opts the intestines to function as a glucose sink, driving uptake of excess glucose and converting it to lactate and Lac-Phe. Notably, the glucose-lowering effect of another biguanide, phenformin, and berberine, a structurally unrelated nutraceutical, similarly depends on intestine-specific mitochondrial complex I inhibition, underscoring a shared therapeutic mechanism.